GRIN2B (Q13224) variants and mutations
GRIN2B (also known as Q13224) is a human protein-coding gene encoding a glutamate receptor ionotropic, NMDA 2B protein. It confers distinct developmental and signaling properties on NMDA receptors and is highly expressed during early brain development. De novo pathogenic variants can cause intellectual disability, developmental delay, epilepsy, abnormal movements, and autism-related phenotypes. This analysis covers 184 GRIN2B variants and mutations. Of these, 98% have computational variant effect predictions. Disease context includes intellectual disability, autosomal dominant 6, developmental and epileptic encephalopathy, 27, and Alzheimer disease. Example GRIN2B variants include M1I, M1T, and V15M.
Variant analysis overview
- Gene: GRIN2B
- Protein: Q13224
- UniProt accession: Q13224
- Organism: Homo sapiens
- Variants analyzed: 184
- Variant scope: all variants
- Completed: 2026-09-07
Variant and mutation evidence
- Variant composition: 29 natural variant; 1 incomplete terminal codon variant; 42 synonymous variants; 104 missense variants; 4 frameshift variants; 1 stop retained variant; 2 stop-gained variants; 1 in-frame deletions; 1 in-frame insertions; 1 substitution
- Prediction scores: 180 variants have prediction scores (98% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: intellectual disability, autosomal dominant 6, developmental and epileptic encephalopathy, 27, Alzheimer disease, Parkinson disease, complex neurodevelopmental disorder, infantile spasms, influenza, infection, major depressive disorder, depressive disorder, alcohol dependence, epilepsy.
Protein structure and variant hotspots
- Protein features: 3 transmembrane segments; 6 binding sites; 24 post-translational modification sites.
- Structural context: 3 variants have structural context.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable GRIN2B variants
Examples include M1I, M1T, V15M, V18I, L19P, L19I, L19Q, R25I. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1I (p.Met1Ile), gnomAD 12-13438009-C-A, CADD 11.40, SIFT 0.04
- M1T (p.Met1Thr), rs117681778, gnomAD 12-13438010-A-G, CADD 15.70, SIFT 0.01
- V15M (p.Val15Met), rs1057519553, MetaLR 0.02, MetaSVM -1.10, Uncertain significance, Epileptic encephalopathy
- V18I (p.Val18Ile), rs201094029, MetaLR 0.02, MetaSVM -0.99, Benign/Likely benign, Intellectual disability, autosomal dominant 6; Developmental and epileptic encep
- L19P (p.Leu19Pro), gnomAD 12-13437995-A-G, CADD 9.84, SIFT 0.20
- L19I (p.Leu19Ile), gnomAD 12-13437996-G-T, CADD 2.35, SIFT 0.12
- L19Q (p.Leu19Gln), rs1947653588, gnomAD 12-13438001-A-T, CADD 9.32, SIFT 0.31
- R25I (p.Arg25Ile), gnomAD 12-13438007-C-A, CADD 18.30, SIFT 0.00
- R27S (p.Arg27Ser), rs1947653525, gnomAD 12-13437988-T-G, CADD 15.00, SIFT 0.01
- R27I (p.Arg27Ile), gnomAD 12-13437989-C-A, CADD 16.50, SIFT 0.00
- R27G (p.Arg27Gly), gnomAD 12-13437990-T-C, CADD 11.90, SIFT 0.01
- K30N (p.Lys30Asn), gnomAD 12-13437964-C-A, CADD 0.03, SIFT 0.12
- K30E (p.Lys30Glu), rs1365989000, gnomAD 12-13437975-T-C, CADD 2.81, SIFT 0.16
- S31I (p.Ser31Ile), rs1947653509, gnomAD 12-13437985-AC-A, CADD 17.50
- P33P (p.Pro33Pro), rs1056194698, gnomAD 12-13437949-C-T, CADD 0.26
- P33Q (p.Pro33Gln), gnomAD 12-13437950-G-T, CADD 14.60, SIFT 0.00
- P33L (p.Pro33Leu), rs191491416, gnomAD 12-13437950-G-A, CADD 14.40, SIFT 0.00
- P33T (p.Pro33Thr), rs1159151781, gnomAD 12-13437951-G-T, CADD 13.90, SIFT 0.00
- P33S (p.Pro33Ser), gnomAD 12-13437951-G-A, CADD 15.10, SIFT 0.00
- I35I (p.Ile35Ile), rs1183396312, gnomAD 12-13437982-G-A, CADD 0.91
- I35T (p.Ile35Thr), rs1947653474, gnomAD 12-13437983-A-G, CADD 6.91, SIFT 0.11
- V39V (p.Val39Val), rs929088439, gnomAD 12-13437970-G-A, CADD 0.36
- V39F (p.Val39Phe), gnomAD 12-13437972-C-A, CADD 4.49, SIFT 0.03
- V42A (p.Val42Ala), rs1947653348, gnomAD 12-13437959-A-G, CADD 5.95, SIFT 0.00
- T44T (p.Thr44Thr), rs1947653335, gnomAD 12-13437955-T-C, CADD 1.27
- T44K (p.Thr44Lys), gnomAD 12-13437956-G-T, CADD 8.24, SIFT 0.13
- T44A (p.Thr44Ala), gnomAD 12-13437957-T-C, CADD 3.42, SIFT 0.39
- T44S (p.Thr44Ser), gnomAD 12-13437957-T-A, CADD 0.98, SIFT 0.60
- I50N (p.Ile50Asn), MetaLR 0.04, MetaSVM -1.04, Uncertain significance
- F59F (p.Phe59Phe), rs1008906468, gnomAD 12-13437943-G-A, CADD 0.22
- F59S (p.Phe59Ser), gnomAD 12-13437944-A-G, CADD 13.50
- A271V (p.Ala271Val), rs138098032, MetaLR 0.01, MetaSVM -0.97, Benign/Likely benign, Inborn genetic diseases; not provided; Intellectual disability, autosomal domina
- L362M (p.Leu362Met), MetaLR 0.70, MetaSVM 0.25, Uncertain significance
- G377R (p.Gly377Arg), rs952850400, []
- E413G (p.Glu413Gly), rs527236034, AlphaMissense 1.00, MetaLR 0.08, Pathogenic, Intellectual disability, autosomal dominant 6; Developmental and epileptic encep
- C436R (p.Cys436Arg), rs1565478152, AlphaMissense 1.00, MetaLR 0.15, Conflicting interpretations, Intellectual disability, autosomal dominant 6
- C456Y (p.Cys456Tyr), rs397514555, AlphaMissense 1.00, MetaLR 0.41, Likely pathogenic, Intellectual disability, autosomal dominant 6
- C461F (p.Cys461Phe), rs1949427787, AlphaMissense 1.00, MetaLR 0.26, Pathogenic/Likely pathogenic, Intellectual disability, autosomal dominant 6; Inborn genetic diseases
- R540H (p.Arg540His), rs672601378, MetaLR 0.25, MetaSVM -0.60, Pathogenic/Likely pathogenic, Inborn genetic diseases; Developmental and epileptic encephalopathy, 27; Intelle
- P553L (p.Pro553Leu), rs397514556, AlphaMissense 1.00, MetaLR 0.49, Likely pathogenic, Developmental and epileptic encephalopathy, 27; Intellectual disability, autosom
- N615I (p.Asn615Ile), rs672601377, AlphaMissense 1.00, MetaLR 0.36, Pathogenic/Likely pathogenic, Developmental and epileptic encephalopathy, 27; Intellectual disability, autosom
- V618G (p.Val618Gly), rs672601376, AlphaMissense 1.00, MetaLR 0.23, Likely pathogenic, Intellectual disability, autosomal dominant 6
- Y646C (p.Tyr646Cys), Conflicting interpretations, Developmental and epileptic encephalopathy, 27; not provided
- N649S (p.Asn649Ser), MetaLR 0.48, MetaSVM 0.14, Conflicting interpretations, not provided; GRIN2B-related complex neurodevelopmental disorder; Developmental
- A652P (p.Ala652Pro), Pathogenic, not provided
- F653V (p.Phe653Val), Uncertain significance, in MRD6
- R682C (p.Arg682Cys), rs387906636, AlphaMissense 0.97, MetaLR 0.24, Pathogenic/Likely pathogenic, Intellectual disability, autosomal dominant 6; Developmental and epileptic encep
- R696H (p.Arg696His), rs1555103971, MetaLR 0.21, MetaSVM -0.76, Pathogenic/Likely pathogenic, Inborn genetic diseases; Intellectual disability, autosomal dominant 6; Developm
- G820E (p.Gly820Glu), rs797044849, AlphaMissense 0.99, MetaLR 0.38, Pathogenic/Likely pathogenic, Developmental and epileptic encephalopathy, 27; Intellectual disability, autosom
- L825V (p.Leu825Val), rs1948651813, AlphaMissense 0.98, MetaLR 0.18, Likely pathogenic, Intellectual disability, autosomal dominant 6
- Q1014R (p.Gln1014Arg), Uncertain significance
- G1026S (p.Gly1026Ser), rs201963596, MetaLR 0.03, MetaSVM -1.10, Conflicting interpretations, Inborn genetic diseases; Intellectual disability, autosomal dominant 6; Developm
- S1415L (p.Ser1415Leu), rs201463390, MetaLR 0.02, MetaSVM -1.08, Conflicting interpretations, not provided; Intellectual disability, autosomal dominant 6; Developmental and e
- S1415S (p.Ser1415Ser), rs150956675, gnomAD 12-13562993-C-T, CADD 8.86
- A1417G (p.Ala1417Gly), rs377105285, gnomAD 12-13562988-G-C, MetaLR 0.01, MetaSVM -1.00
- A1417T (p.Ala1417Thr), rs866929842, gnomAD 12-13562989-C-T, MetaLR 0.02, MetaSVM -0.98
- A1417S (p.Ala1417Ser), rs866929842, gnomAD 12-13562989-C-A, MetaLR 0.01, MetaSVM -0.95
- R1418R (p.Arg1418Arg), rs75988134, gnomAD 12-13562984-C-T, CADD 11.90
- P1419P (p.Pro1419Pro), rs761174489, gnomAD 12-13562981-C-T, CADD 5.75
- P1419L (p.Pro1419Leu), rs200269512, gnomAD 12-13562982-G-A, MetaLR 0.02, MetaSVM -0.96
- P1419T (p.Pro1419Thr), rs1363559243, gnomAD 12-13562983-G-T, MetaLR 0.02, MetaSVM -0.96
- D1420D (p.Asp1420Asp), gnomAD 12-13562978-G-A, CADD 9.61
- D1420G (p.Asp1420Gly), gnomAD 12-13562979-T-C, MetaLR 0.06, MetaSVM -1.16
- D1420N (p.Asp1420Asn), gnomAD 12-13562980-C-T, MetaLR 0.03, MetaSVM -1.06
- D1420H (p.Asp1420His), gnomAD 12-13562980-C-G, MetaLR 0.08, MetaSVM -1.14
- F1421L (p.Phe1421Leu), rs879254129, gnomAD 12-13562977-A-G, MetaLR 0.02, MetaSVM -1.07
- R1422R (p.Arg1422Arg), gnomAD 12-13562972-C-T, CADD 8.16
- R1422Q (p.Arg1422Gln), rs75269586, gnomAD 12-13562973-C-T, MetaLR 0.04, MetaSVM -1.12
- R1422L (p.Arg1422Leu), rs75269586, gnomAD 12-13562973-C-A, MetaLR 0.05, MetaSVM -1.12
- R1422W (p.Arg1422Trp), rs773278200, gnomAD 12-13562974-G-A, MetaLR 0.08, MetaSVM -1.13
- A1423A (p.Ala1423Ala), rs1565452665, gnomAD 12-13562969-G-A, CADD 12.00
- A1423T (p.Ala1423Thr), gnomAD 12-13562971-C-T, MetaLR 0.01, MetaSVM -0.93
- L1424F (p.Leu1424Phe), rs748128078, MetaLR 0.02, MetaSVM -1.04, Benign, Intellectual disability, autosomal dominant 6; Developmental and epileptic encep
- V1425I (p.Val1425Ile), gnomAD 12-13562965-C-T, MetaLR 0.02, MetaSVM -1.03
- N1427K (p.Asn1427Lys), rs1214699233, gnomAD 12-13562957-G-T, MetaLR 0.01, MetaSVM -1.05
- N1427N (p.Asn1427Asn), gnomAD 12-13562957-G-A, CADD 8.56
- N1427S (p.Asn1427Ser), rs1948568369, gnomAD 12-13562958-T-C, MetaLR 0.00, MetaSVM -0.97
- K1428R (p.Lys1428Arg), rs774504887, gnomAD 12-13562955-T-C, MetaLR 0.01, MetaSVM -1.02
- P1429P (p.Pro1429Pro), rs146235271, gnomAD 12-13562951-C-G, CADD 3.17
- P1429L (p.Pro1429Leu), rs1261054497, gnomAD 12-13562952-G-A, MetaLR 0.02, MetaSVM -0.97
- P1429S (p.Pro1429Ser), gnomAD 12-13562953-G-A, MetaLR 0.01, MetaSVM -0.93
- V1430V (p.Val1430Val), rs1029997173, gnomAD 12-13562948-C-T, CADD 10.30
- V1430A (p.Val1430Ala), rs780022796, gnomAD 12-13562949-A-G, MetaLR 0.01, MetaSVM -1.00
- V1430M (p.Val1430Met), rs879253885, gnomAD 12-13562950-C-T, MetaLR 0.02, MetaSVM -0.92
- V1431V (p.Val1431Val), rs1948567946, gnomAD 12-13562945-G-C, CADD 7.95
- S1432S (p.Ser1432Ser), rs755880051, gnomAD 12-13562942-C-G, CADD 7.46
- S1432L (p.Ser1432Leu), rs1555101579, gnomAD 12-13562943-G-A, MetaLR 0.02, MetaSVM -1.01
- A1433A (p.Ala1433Ala), rs745715225, gnomAD 12-13562939-G-T, CADD 10.70
- L1434F (p.Leu1434Phe), gnomAD 12-13562937-AG-A, CADD 33.00
- L1434I (p.Leu1434Ile), rs1002108827, gnomAD 12-13562938-G-T, MetaLR 0.02, MetaSVM -0.93
- H1435H (p.His1435His), rs201809938, gnomAD 12-13562933-A-G, CADD 5.09
- H1435N (p.His1435Asn), rs1200161647, gnomAD 12-13562935-G-T, MetaLR 0.02, MetaSVM -1.06
- G1436G (p.Gly1436Gly), rs1369468359, gnomAD 12-13562930-C-T, CADD 10.90
- G1436A (p.Gly1436Ala), rs1565452616, gnomAD 12-13562931-C-G, MetaLR 0.02, MetaSVM -1.06
- G1436E (p.Gly1436Glu), gnomAD 12-13562931-C-T, MetaLR 0.02, MetaSVM -0.98
- G1436R (p.Gly1436Arg), rs1948567613, gnomAD 12-13562932-C-T, MetaLR 0.02, MetaSVM -0.96
- A1437A (p.Ala1437Ala), rs112265127, gnomAD 12-13562927-G-A, CADD 8.56
- A1437P (p.Ala1437Pro), rs1948567505, gnomAD 12-13562928-GC-G, CADD 32.00
- A1437V (p.Ala1437Val), rs1948567394, gnomAD 12-13562928-G-A, MetaLR 0.02, MetaSVM -0.99
- A1437T (p.Ala1437Thr), rs797045608, gnomAD 12-13562929-C-T, MetaLR 0.02, MetaSVM -0.99
- V1438V (p.Val1438Val), rs1384732217, gnomAD 12-13562924-C-T, CADD 8.73
- V1438M (p.Val1438Met), rs763699668, gnomAD 12-13562926-C-T, MetaLR 0.05, MetaSVM -1.19
- V1438L (p.Val1438Leu), rs763699668, gnomAD 12-13562926-C-A, MetaLR 0.03, MetaSVM -1.04
- P1439A (p.Pro1439Ala), rs758042475, AlphaMissense 0.08, MetaLR 0.01, Uncertain significance, Inborn genetic diseases; Landau-Kleffner syndrome; Intellectual disability, auto
- A1440A (p.Ala1440Ala), rs199570238, gnomAD 12-13562918-G-T, CADD 10.30
- A1440V (p.Ala1440Val), rs767037011, gnomAD 12-13562919-G-A, MetaLR 0.02, MetaSVM -1.03
- A1440D (p.Ala1440Asp), gnomAD 12-13562919-G-T, MetaLR 0.02, MetaSVM -1.03
- A1440S (p.Ala1440Ser), rs754377600, gnomAD 12-13562920-C-A, MetaLR 0.01, MetaSVM -1.00
- R1441L (p.Arg1441Leu), rs200903876, gnomAD 12-13562916-C-A, MetaLR 0.08, MetaSVM -1.12
- R1441P (p.Arg1441Pro), rs200903876, gnomAD 12-13562916-C-G, MetaLR 0.05, MetaSVM -1.11
- R1441H (p.Arg1441His), rs200903876, gnomAD 12-13562916-C-T, MetaLR 0.03, MetaSVM -1.09
- R1441C (p.Arg1441Cys), rs773648473, gnomAD 12-13562917-G-A, MetaLR 0.10, MetaSVM -1.02
- F1442F (p.Phe1442Phe), gnomAD 12-13562912-G-A, CADD 10.90
- Q1443P (p.Gln1443Pro), rs1431504653, gnomAD 12-13562910-T-G, MetaLR 0.01, MetaSVM -0.91
- K1444T (p.Lys1444Thr), gnomAD 12-13562907-T-G, MetaLR 0.04, MetaSVM -1.12
- K1444E (p.Lys1444Glu), rs768707460, gnomAD 12-13562908-T-C, MetaLR 0.04, MetaSVM -1.08
- p.Ile1446dup, rs1310969670, gnomAD 12-13562899-A-AGA, CADD 18.70
- I1446I (p.Ile1446Ile), gnomAD 12-13562900-G-T, CADD 9.33
- I1446T (p.Ile1446Thr), rs1301106301, gnomAD 12-13562901-A-G, MetaLR 0.02, MetaSVM -0.99
- I1446S (p.Ile1446Ser), gnomAD 12-13562901-A-C, MetaLR 0.02, MetaSVM -1.01
- I1446V (p.Ile1446Val), rs1477589166, gnomAD 12-13562902-T-C, MetaLR 0.01, MetaSVM -1.01
- C1447C (p.Cys1447Cys), rs766970197, gnomAD 12-13562897-A-G, CADD 12.40
- C1447Y (p.Cys1447Tyr), rs749417978, gnomAD 12-13562898-C-T, MetaLR 0.02, MetaSVM -1.04
- I1448M (p.Ile1448Met), gnomAD 12-13562894-T-C, MetaLR 0.03, MetaSVM -1.08
- I1448T (p.Ile1448Thr), rs1482150457, gnomAD 12-13562895-A-G, MetaLR 0.03, MetaSVM -1.14
- I1448V (p.Ile1448Val), rs1948566354, gnomAD 12-13562896-T-C, MetaLR 0.03, MetaSVM -1.05
- G1449G (p.Gly1449Gly), gnomAD 12-13562891-C-G, CADD 10.30
- G1449E (p.Gly1449Glu), rs1255397067, gnomAD 12-13562892-C-T, MetaLR 0.03, MetaSVM -1.11
- N1450K (p.Asn1450Lys), gnomAD 12-13562888-G-C, MetaLR 0.02, MetaSVM -0.96
- Q1451H (p.Gln1451His), rs781050985, gnomAD 12-13562885-C-G, MetaLR 0.01, MetaSVM -0.98
- Q1451K (p.Gln1451Lys), rs745597964, gnomAD 12-13562887-G-T, MetaLR 0.02, MetaSVM -0.98
- S1452F (p.Ser1452Phe), rs756790727, MetaLR 0.03, MetaSVM -1.08, Conflicting interpretations, Developmental and epileptic encephalopathy, 27; Intellectual disability, autosom
- N1453K (p.Asn1453Lys), rs887589398, gnomAD 12-13562879-G-T, MetaLR 0.02, MetaSVM -0.99
- N1453D (p.Asn1453Asp), rs746663430, gnomAD 12-13562881-T-C, MetaLR 0.03, MetaSVM -1.01
- P1454R (p.Pro1454Arg), rs1482794279, gnomAD 12-13562877-G-C, MetaLR 0.07, MetaSVM -1.14
- P1454S (p.Pro1454Ser), rs1948565765, gnomAD 12-13562878-G-A, MetaLR 0.04, MetaSVM -1.13
- P1454A (p.Pro1454Ala), gnomAD 12-13562878-G-C, MetaLR 0.03, MetaSVM -1.07
- C1455C (p.Cys1455Cys), gnomAD 12-13562873-A-G, CADD 12.20
- C1455* (p.Cys1455Ter), rs1555101527, gnomAD 12-13562873-A-T, CADD 40.00
- C1455Y (p.Cys1455Tyr), gnomAD 12-13562874-C-T, MetaLR 0.01, MetaSVM -0.92
- V1456V (p.Val1456Val), gnomAD 12-13562870-C-G, CADD 9.04
- P1457R (p.Pro1457Arg), gnomAD 12-13562868-G-C, MetaLR 0.02, MetaSVM -1.06
- P1457S (p.Pro1457Ser), rs1317229312, gnomAD 12-13562869-G-A, MetaLR 0.01, MetaSVM -0.95
- N1458N (p.Asn1458Asn), gnomAD 12-13562864-G-A, CADD 8.47
- N1458S (p.Asn1458Ser), rs577649736, gnomAD 12-13562865-T-C, MetaLR 0.03, MetaSVM -1.03
- N1459del (p.Asn1459del), gnomAD 12-13562858-TTTG-, CADD 18.90
- N1459D (p.Asn1459Asp), rs1384338205, gnomAD 12-13562863-T-C, MetaLR 0.03, MetaSVM -1.07
- K1460K (p.Lys1460Lys), rs369455429, gnomAD 12-13562858-T-C, CADD 10.50
- K1460R (p.Lys1460Arg), rs757954618, gnomAD 12-13562859-T-C, MetaLR 0.02, MetaSVM -0.96
- N1461T (p.Asn1461Thr), gnomAD 12-13562855-GT-G, CADD 32.00
- N1461S (p.Asn1461Ser), rs1336696438, gnomAD 12-13562856-T-C, MetaLR 0.02, MetaSVM -1.03
- P1462L (p.Pro1462Leu), rs1948564811, gnomAD 12-13562853-G-A, MetaLR 0.10, MetaSVM -1.08
- P1462S (p.Pro1462Ser), rs780659331, gnomAD 12-13562854-G-A, MetaLR 0.06, MetaSVM -1.12
- R1463T (p.Arg1463Thr), rs1408420096, gnomAD 12-13562850-C-G, MetaLR 0.11, MetaSVM -0.98
- A1464D (p.Ala1464Asp), gnomAD 12-13562847-G-T, MetaLR 0.02, MetaSVM -1.01
- A1464V (p.Ala1464Val), gnomAD 12-13562847-G-A, MetaLR 0.01, MetaSVM -0.91
- A1464P (p.Ala1464Pro), rs1168549804, gnomAD 12-13562848-C-G, MetaLR 0.01, MetaSVM -0.91
- G1467G (p.Gly1467Gly), rs1461672749, gnomAD 12-13562837-G-A, CADD 9.54
- G1467A (p.Gly1467Ala), rs200127692, gnomAD 12-13562838-C-G, MetaLR 0.03, MetaSVM -1.07
- G1467S (p.Gly1467Ser), rs1190416870, gnomAD 12-13562839-C-T, MetaLR 0.02, MetaSVM -1.06
- S1468S (p.Ser1468Ser), rs756658425, gnomAD 12-13562834-G-A, CADD 10.10
- S1468C (p.Ser1468Cys), gnomAD 12-13562835-G-C, MetaLR 0.02, MetaSVM -1.02
- S1469R (p.Ser1469Arg), gnomAD 12-13562831-G-C, MetaLR 0.11, MetaSVM -1.01
- S1469N (p.Ser1469Asn), rs202133231, gnomAD 12-13562832-C-T, MetaLR 0.05, MetaSVM -1.11
- N1470K (p.Asn1470Lys), gnomAD 12-13562828-A-C, MetaLR 0.09, MetaSVM -1.09
- N1470N (p.Asn1470Asn), rs199819153, gnomAD 12-13562828-A-G, CADD 9.04
- N1470S (p.Asn1470Ser), rs201145829, gnomAD 12-13562829-T-C, MetaLR 0.10, MetaSVM -1.03
- G1471G (p.Gly1471Gly), rs202051424, gnomAD 12-13562825-C-T, CADD 9.54
- H1472Q (p.His1472Gln), gnomAD 12-13562822-A-T, MetaLR 0.05, MetaSVM -1.16
- H1472H (p.His1472His), gnomAD 12-13562822-A-G, CADD 9.30
- V1473V (p.Val1473Val), rs1184165091, gnomAD 12-13562819-A-G, CADD 9.58
- V1473I (p.Val1473Ile), rs1948563862, gnomAD 12-13562821-C-T, MetaLR 0.11, MetaSVM -1.05
- E1475* (p.Glu1475Ter), rs1555101495, gnomAD 12-13562815-C-A, CADD 39.00
- L1477V (p.Leu1477Val), rs1388986519, gnomAD 12-13562809-G-C, MetaLR 0.08, MetaSVM -1.13
- S1478S (p.Ser1478Ser), rs1462553586, gnomAD 12-13562804-A-G, CADD 12.70
- S1478P (p.Ser1478Pro), rs910793751, gnomAD 12-13562806-A-G, MetaLR 0.02, MetaSVM -1.08
- S1479S (p.Ser1479Ser), rs1948563409, gnomAD 12-13562801-A-G, CADD 10.70
- I1480I (p.Ile1480Ile), rs1427283813, gnomAD 12-13562798-A-T, CADD 9.62
- S1482S (p.Ser1482Ser), gnomAD 12-13562792-A-G, CADD 11.60
- S1482Y (p.Ser1482Tyr), gnomAD 12-13562793-G-T, MetaLR 0.18, MetaSVM -0.82
Public GRIN2B analysis runs
- GRIN2B analysis run — GRIN2B (184 variants) — completed 2026-09-07
- GRIN2B analysis run — GRIN2B (2,433 variants) — completed 2026-08-20